A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Br J Dermatol
; 182(6): 1348-1358, 2020 06.
Article
in En
| MEDLINE
| ID: mdl-31887225
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Psoriasis
/
Quality of Life
Type of study:
Clinical_trials
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Adult
/
Humans
Language:
En
Journal:
Br J Dermatol
Year:
2020
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom